We found that MHC-II blockade significantly reduced exosome-dependent T-cell activation (Figure 3E), confirming that an antigen-presenting activity of MILD COVID-19 patient exosomes was the actual driving force of CD4+ T-cell activation. The gene discussed is CD4; the disease is COVID-19.